TNF Pharmaceuticals (TNFA) said Wednesday that Prevail Partners has agreed to acquire 283,019 common shares of the company at $2.12 apiece.
TNF said it has engaged Prevail Partners affiliate Prevail InfoWorks to offer clinical services for the next phase 2 clinical study using TNF's sarcopenia drug candidate.
The company said it is now fully funded for clinical trials for the next two years.
TNF shares were up 3.9% in recent trading.
Price: 1.51, Change: +0.06, Percent Change: +3.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.